Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy(VIALE-M)

Grants and Contracts Details

StatusFinished
Effective start/end date7/17/20 → 3/13/23

Funding

  • AbbVie Incorporated: $24,425.00